One year in review 2017: systemic vasculitis

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):5-26. Epub 2017 Mar 29.

Abstract

Systemic vasculitis is a group of heterogeneous, disabling disorders. Great interest has recently arisen in pathophysiology, clinical phenotypes and therapy of large- and small-vessel vasculitis. The general work hypothesis has been to promote research focused on disease-related pathogenetic pathways, with the ultimate goal of identifying novel diagnostic and prognostic biomarkers, thus leading towards more effective targeted treatments. Following the previous annual reviews of this series, we will hereby provide a critical digest of the recent literature on small- and large-vessel systemic vasculitis, with a specific focus on novel possible disease-related biomarkers and their impact on current and future therapies.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Antineutrophil Cytoplasmic / blood
  • Biomarkers / blood
  • Cryoglobulinemia / blood
  • Cryoglobulinemia / diagnosis
  • Cryoglobulinemia / drug therapy
  • Cryoglobulinemia / immunology
  • Granulomatosis with Polyangiitis / blood
  • Granulomatosis with Polyangiitis / diagnosis
  • Granulomatosis with Polyangiitis / drug therapy
  • Granulomatosis with Polyangiitis / immunology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Inflammation Mediators / blood
  • Predictive Value of Tests
  • Prognosis
  • Systemic Vasculitis* / blood
  • Systemic Vasculitis* / diagnosis
  • Systemic Vasculitis* / drug therapy
  • Systemic Vasculitis* / immunology

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Antineutrophil Cytoplasmic
  • Biomarkers
  • Immunosuppressive Agents
  • Inflammation Mediators